Q1 Earnings Estimate for Penumbra Issued By Leerink Partnrs

Penumbra, Inc. (NYSE:PEN - Free Report) - Equities researchers at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Penumbra in a research note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of $0.69 per share for the quarter, down from their previous forecast of $0.83. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra's Q2 2025 earnings at $0.83 EPS, FY2025 earnings at $3.61 EPS and FY2026 earnings at $5.54 EPS.

PEN has been the subject of a number of other reports. StockNews.com upgraded Penumbra from a "hold" rating to a "buy" rating in a report on Thursday, February 20th. Oppenheimer began coverage on shares of Penumbra in a research note on Tuesday, December 17th. They issued an "outperform" rating and a $275.00 price objective for the company. UBS Group upped their target price on shares of Penumbra from $305.00 to $320.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. raised their price target on shares of Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Finally, Citigroup upped their price objective on Penumbra from $220.00 to $245.00 and gave the stock a "neutral" rating in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Penumbra presently has a consensus rating of "Moderate Buy" and a consensus target price of $292.64.

Penumbra Trading Down 2.3 %

NYSE:PEN traded down $6.55 on Friday, reaching $281.15. The company's stock had a trading volume of 502,240 shares, compared to its average volume of 530,458. Penumbra has a 12-month low of $148.00 and a 12-month high of $310.00. The stock has a 50 day moving average price of $259.90 and a 200 day moving average price of $229.52. The firm has a market cap of $10.83 billion, a price-to-earnings ratio of 826.92, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last posted its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million.

Insider Activity

In other news, Director Harpreet Grewal sold 167 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the sale, the director now owns 8,530 shares in the company, valued at approximately $2,058,118.40. The trade was a 1.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $244.49, for a total transaction of $146,694.00. Following the completion of the transaction, the executive vice president now directly owns 63,444 shares in the company, valued at $15,511,423.56. This trade represents a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,219 shares of company stock worth $4,426,439. 5.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Penumbra

Several large investors have recently bought and sold shares of PEN. Polar Asset Management Partners Inc. lifted its holdings in shares of Penumbra by 10.5% in the 4th quarter. Polar Asset Management Partners Inc. now owns 122,126 shares of the company's stock valued at $29,002,000 after purchasing an additional 11,605 shares during the last quarter. Cache Advisors LLC acquired a new position in Penumbra during the fourth quarter worth approximately $534,000. Public Employees Retirement System of Ohio lifted its stake in Penumbra by 6.2% in the fourth quarter. Public Employees Retirement System of Ohio now owns 22,399 shares of the company's stock valued at $5,319,000 after buying an additional 1,316 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Penumbra by 14.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 111,500 shares of the company's stock valued at $26,479,000 after acquiring an additional 13,929 shares during the period. Finally, Woodline Partners LP grew its position in shares of Penumbra by 396.0% during the fourth quarter. Woodline Partners LP now owns 25,323 shares of the company's stock worth $6,014,000 after acquiring an additional 20,218 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.